MeiraGTx Holdings plc
MGTXAbout the company
MeiraGTx Holdings plc, a clinical-stage genetic medicines company, focusing on developing treatments for patients with serious diseases. The company develops various therapies for ocular diseases, including inherited retinal diseases and large degenerative ocular diseases; neurodegenerative diseases; and xerostomia.
Investment snapshot
Positive
2
BUY / PASS
Neutral / negative
2 / 12
NEUTRAL / FAIL
Median fair value
—
No comparable estimates
Models with upside
0 / 17
Positive margin of safety
Key risk
No clean pass — all 13 investors flag at least one valuation criterion
Framework analysis
| Verdict | Meaning |
|---|---|
| BUY | Positive purchase signal: the framework's buy requirements are met. |
| PASS | The company clears the framework's checklist or screen, but the framework does not produce a buy signal. For valuation frameworks this often means margin of safety is missing, insufficient, or unavailable; some screen-only frameworks have no intrinsic-value BUY state. |
| NEUTRAL | Neither a positive nor negative conclusion. It does not mean to hold an existing position. |
| FAIL | The company does not clear the framework's requirements. |
| Ranked | Ranked strategies do not use PASS: selected cohort is BUY, outside the cohort is FAIL, and unranked is NEUTRAL. |
Current investor scores use trailing 12-month flows and the latest balance sheet where supported. Multi-year and EPS tests retain annual history; each framework shows its financial basis below. Intrinsic values use annual financials.
| Metric | Graham Defensive Value | Buffett Quality Compounder | Lynch GARP | Greenblatt Magic Formula | Piotroski F-Score | Dreman Contrarian Value | Munger Quality Focus | Pabrai Dhandho Framework | Akre Three-Legged Stool | Marks Risk-Aware Value | Ackman Activist Value | Templeton Global Bargain Hunter | Sleep Scale Economies Shared | Asness Systematic Factors | Neff Low-P/E Total Return | Schloss Asset-Value Discipline | O'Shaughnessy Systematic Factor Composite |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Verdict | FAIL | FAIL | FAIL | FAIL · Rank #2756 (Top 89%) | PASS | FAIL | FAIL | FAIL | FAIL | FAIL | PASS | FAIL | FAIL | NEUTRAL | FAIL | FAIL | NEUTRAL |
| Score | |||||||||||||||||
| Analysis | Checking access… | Checking access… | Checking access… | Checking access… | Checking access… | Checking access… | Checking access… | Checking access… | Checking access… | Checking access… | Checking access… | Checking access… | Checking access… | Checking access… | Checking access… | Checking access… | Checking access… |
| Intrinsic Value (annual) | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Margin of Safety | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Financial Basis | TTM ended 2026-09-30 · Balance sheet at 2026-09-30 · Annual history · FY 2025 Latest source filing: 2026-11-12 Score computed: 2026-11-14 | Annual history · FY 2025 Latest source filing: 2026-03-30 Score computed: 2026-11-14 | Annual history · FY 2025 · Balance sheet at 2026-09-30 · TTM ended 2026-09-30 vs 2025-09-30 · TTM ended 2026-09-30 Latest source filing: 2026-11-12 Score computed: 2026-11-14 | Annual history · FY 2025 Latest source filing: 2026-03-30 Score computed: 2026-11-14 | Annual history · FY 2025 Latest source filing: 2026-03-30 Score computed: 2026-11-14 | Annual history · FY 2025 · TTM ended 2026-09-30 · Balance sheet at 2026-09-30 · Market data at 2026-11-01 Latest source filing: 2026-11-12 Score computed: 2026-11-14 | Qualitative assessment · Annual history · FY 2025 · TTM ended 2026-09-30 · Balance sheet at 2026-09-30 Latest source filing: 2026-11-12 Score computed: 2026-11-14 | Qualitative assessment · Annual history · FY 2025 Latest source filing: 2026-03-30 Score computed: 2026-11-14 | Annual history · FY 2025 · Qualitative assessment · TTM ended 2026-09-30 · Balance sheet at 2026-09-30 Latest source filing: 2026-11-12 Score computed: 2026-11-14 | Annual history · FY 2025 · Qualitative assessment Latest source filing: 2026-03-30 Score computed: 2026-11-14 | Annual history · FY 2025 · TTM ended 2026-09-30 · Balance sheet at 2026-09-30 · Market data at 2026-11-01 Latest source filing: 2026-11-12 Score computed: 2026-11-14 | Annual history · FY 2025 · Price history 2025-01-01–2026-11-01 · Balance sheet at 2026-09-30 Latest source filing: 2026-11-12 Score computed: 2026-11-14 | Annual history · FY 2025 · Qualitative assessment Latest source filing: 2026-03-30 Score computed: 2026-11-14 | TTM ended 2026-09-30 · Balance sheet at 2026-09-30 · Price history 2025-01-01–2026-11-01 · Annual history · FY 2025 Latest source filing: 2026-11-12 Score computed: 2026-11-14 | Annual history · FY 2025 · TTM ended 2026-09-30 Latest source filing: 2026-11-12 Score computed: 2026-11-14 | Annual history · FY 2025 · Balance sheet at 2026-09-30 Latest source filing: 2026-11-12 Score computed: 2026-11-14 | TTM ended 2026-09-30 · Annual history · FY 2025 · Price history 2025-01-01–2026-11-01 Latest source filing: 2026-11-12 Score computed: 2026-11-14 |
Where It Passes
Where It Falls Short
- Valuation0% pass✓ 1✗ 27▾
No clean pass — all 13 investors flag at least one valuation criterion
Net income / market capitalization+8.73%; #852/6340 (top 13.4%)✓AsnessTop 30% of eligible cross-section✗OshaughnessyTop 10% of eligible cross-sectionPrice / 3-yr avg EPS✗Graham<= 15xPrice-to-Book Ratio✗Graham<= 1.5xP/E x P/B✗Graham<= 22.5Basic earnings-growth PEG (dividends excluded)✗Lynch< 1.0 (ideally < 0.5)EBIT / Enterprise Value-11.7%✗Greenblatt> 10%Earnings Yield + ROC AssessmentEY=-11.7%, ROC=-1212.4%✗GreenblattBoth EY > 10% and ROC > 25%Price / EPS✗Dreman< 12x✗Templeton< 12x (fixed ceiling; proxy for the market's cheapest 40%)Price / (CFO / Shares)N/A (negative CFPS)✗Dreman< 8xPrice / Book Value per ShareN/A (negative BVPS)✗Dreman< 1.2x✗Templeton< 1.5x✗SchlossP/B <= 0.80x (app cutoff)Valuation ReasonablenessOE Yield=-14.1%✗MungerP/E < 25 or Owner Earnings Yield > 5%P/E or FCF YieldFCF Yield=-5.6%✗PabraiP/E < 15 or FCF Yield > 10%P/B or P/E vs. Historical Average✗MarksP/E < 15 or P/B < 2.0Discount to Intrinsic ValueN/A (negative normalized EPS)✗Marks>= 20% below intrinsic valuePrice / FCF per ShareN/A (negative FCF)✗Ackman<= 25Price vs. Trailing Low179% of trailing low ($5.12)✗Templeton<= 120% of trailing low (certified split-adjusted live window)Positive book equity / market capitalization+0.2399; #3979/6449 (top 61.7%)✗AsnessTop 30% of eligible cross-sectionPrice / Diluted EPS✗NeffP/E <= 15x (app proxy for a P/E 40%-60% below the market)(EPS CAGR % + Dividend Yield %) / P/E✗Neff> 0.7 (Neff's published traditional edge)Price / Tangible Book Value per ShareN/A (non-positive TBVPS)✗SchlossP/TBV <= 1.00x (app cutoff)Book Value per Share Change-101.3%✗SchlossLatest BVPS >= earliest BVPS over >= 3 years (app rule)Revenue / market capitalization+0.4480; #2778/5247 (top 52.9%)✗OshaughnessyTop 10% of eligible cross-section(Operating cash flow - capex) / market capitalization-0.33%; #2586/4519 (top 57.2%)✗OshaughnessyTop 10% of eligible cross-sectionTrailing six-month price return through the evaluation date+2.34%; #2370/6202 (top 38.2%)✗OshaughnessyTop 10% of eligible cross-section - Cash Flow0% pass✓ 1✗ 11▾
No clean pass — all 10 investors flag at least one cash flow criterion
Free Cash Flow Proxy$-105.5M✗BuffettPositive and growingFCF Positive and Growing$-3.0M✗LynchPositive and growingOperating Cash Flow$-46.4M✗PiotroskiCFO > 0(CFO / Total Assets) vs ROACFO/Assets=-18.97%, ROA=-46.72%✓PiotroskiCFO/Assets > ROAPrice / (CFO / Shares)N/A (negative CFPS)✗Dreman< 8xP/E or FCF YieldFCF Yield=-5.6%✗PabraiP/E < 15 or FCF Yield > 10%FCF Positive1/9 years FCF positive✗MarksPositive FCF in majority of recent years(OCF - CapEx) / Market Cap-0.4%✗Ackman>= 4%Price / FCF per ShareN/A (negative FCF)✗Ackman<= 25Positive Operating Cash Flow frequency1/9 years positive✗SleepPositive OCF in >= 70% of available yearsOperating Cash Flow - Capital Expenditures$-3.0M✗Neff> $0 (app proxy for a strong fundamental case)(Operating cash flow - capex) / market capitalization-0.33%; #2586/4519 (top 57.2%)✗OshaughnessyTop 10% of eligible cross-section - Profitability13% pass✓ 10✗ 25▾
14 of 16 flag MGTX's profitability — Graham, Buffett, Lynch +11 more
Net income / market capitalization+8.73%; #852/6340 (top 13.4%)✓AsnessTop 30% of eligible cross-section✗OshaughnessyTop 10% of eligible cross-sectionPositive EPS (10 years)0/10 years positive✗GrahamPositive EPS every year for 10 yearsEPS Growth (3-yr avg, 10-yr window)N/A (negative base EPS)✗Graham>= 33% growthNet Income Positive (10+ years)0/10 years positive✗BuffettPositive every year for 10+ yearsROE (up to 5-year arithmetic mean)-91.2%✗Buffett> 15% arithmetic mean (app rule)Operating Margin (10-yr trend)-130.2% (latest)✗BuffettStable or rising over 10 yearsFree Cash Flow Proxy$-105.5M✗BuffettPositive and growingEarnings Variance (10-yr CoV)N/A (negative mean EPS)✗BuffettCoV < 0.3Retained Earnings Effectiveness✗Buffett$1 retained -> > $1 market value createdBasic earnings-growth PEG (dividends excluded)✗Lynch< 1.0 (ideally < 0.5)3-5 Year EPS CAGR✗Lynch15-30% (Fast Grower); > 0% to passROE36.4%✓Lynch> 15%EBIT / Enterprise Value-11.7%✗Greenblatt> 10%Earnings Yield + ROC AssessmentEY=-11.7%, ROC=-1212.4%✗GreenblattBoth EY > 10% and ROC > 25%Net Income / Total Assets-46.72%✗PiotroskiROA > 0ROA Change YoY-54.79% -> -46.72% (delta: +8.07%)✓PiotroskiCurrent ROA > Prior ROA(CFO / Total Assets) vs ROACFO/Assets=-18.97%, ROA=-46.72%✓PiotroskiCFO/Assets > ROAGross Margin Change YoY✗PiotroskiImproved YoYPre-Tax Income / Revenue-140.3%✗Dreman>= 8%Net Income / Shareholders' Equity36.4%✓Dreman> 12%Margin of Safety✗PabraiP/B < 1.5 or P/E < 15Return on Equity-129.6% (3-yr avg)✗AkreROE > 20% (3-year avg)Discount to Intrinsic ValueN/A (negative normalized EPS)✗Marks>= 20% below intrinsic valuePositive Net Income Frequency0/9 years positive✗MarksPositive net income in >= 7 of last 10 yearsOperating Income / Revenue44.8%✓Ackman>= 15%Net Income / Shareholders Equity36.4%✓Ackman>= 15%5-Year EPS CAGR✗Templeton> 0% (5-year EPS CAGR)Operating Margin Trend-977.8% (2023) -> -130.2% (2025)✓TempletonNon-negative operating-margin trend over 3 yearsRevenue growth vs. gross and operating margin trendrevenue up, operating margin -977.8% -> -130.2%✓SleepRevenue rising; gross margin flat or falling; operating margin holdingGross profit / total assets✗AsnessTop 30% of eligible cross-sectionNet income / positive book equity+36.37%; #342/5226 (top 6.5%)✓AsnessTop 30% of eligible cross-sectionNegative 5-year standard deviation of ROA-0.1173; #3675/5884 (top 62.5%)✗AsnessTop 30% of eligible cross-section3-5 Year Diluted EPS CAGR✗Neff7%-20% annualizedPositive Diluted-EPS Years0/9 years positive✗Schloss>= 70% positive over 5-10 observed years (app rule) - Growth13% pass✓ 3✗ 10▾
7 of 8 flag MGTX's growth — Graham, Lynch, Dreman +4 more
EPS Growth (3-yr avg, 10-yr window)N/A (negative base EPS)✗Graham>= 33% growthBasic earnings-growth PEG (dividends excluded)✗Lynch< 1.0 (ideally < 0.5)3-5 Year EPS CAGR✗Lynch15-30% (Fast Grower); > 0% to passInventory Growth vs Revenue Growth✗LynchInventory growth < Revenue growthEPS Growth Direction$-3.72 (2017) -> $-1.42 (2025)✗DremanPositive over recent yearsEPS CAGR✗Dreman> 5% annualizedPositive Net Income Frequency0/9 years positive✗MarksPositive net income in >= 7 of last 10 years3yr Median Revenue Growth137.4%✓Ackman>= 5%Positive EPS Growth Frequency2/5 years with positive EPS growth✗AckmanPositive EPS growth in >= 3 of last 5 years5-Year EPS CAGR✗Templeton> 0% (5-year EPS CAGR)Revenue growth vs. gross and operating margin trendrevenue up, operating margin -977.8% -> -130.2%✓SleepRevenue rising; gross margin flat or falling; operating margin holding5-year Revenue CAGR39.2%✓SleepCAGR > 7%3-5 Year Diluted EPS CAGR✗Neff7%-20% annualized - Verdicts13% pass✓ 2✗ 13▾
Split decision: 12 FAIL · 2 PASS · 2 NEUTRAL
Overall verdict✗GrahamFAIL (2/9)✗BuffettFAIL (0/9)✗LynchFAIL (1/7)✗GreenblattRank #2756✓PiotroskiPASS (F-Score 4)✗DremanFAIL (3/11)✗MungerFAIL (1/4)✗PabraiFAIL (0/3)✗AkreFAIL (1/6)✗MarksFAIL (0/5)✓AckmanPASS (5/9)✗TempletonFAIL (3/8)✗SleepFAIL (2/6)•AsnessNEUTRAL (Not ranked)✗NeffFAIL (1/6)✗SchlossFAIL (2/7)•OshaughnessyNEUTRAL (Not ranked) - Efficiency38% pass✓ 4✗ 7▾
5 of 8 flag MGTX's efficiency — Buffett, Greenblatt, Piotroski +2 more
Current Ratio4.62✓Graham>= 2.0ROIC (3-5 yr avg)-786.2%✗Buffett> 10%ROIC - WACC-796.2%✗BuffettPositive (WACC = 10%)EBIT / (NWC + Net Fixed Assets)-1212.4%✗Greenblatt> 25%Current Ratio Change YoY2.03 -> 0.75✗PiotroskiIncreased YoYRevenue / Total Assets Change YoY0.12x -> 0.33x✓PiotroskiImproved YoYCurrent Assets / Current Liabilities4.62✓Dreman> 1.5Return on Invested Capital42.2%✓Munger> 15%ROIC (high and growing)FY2023: ROIC=-51.5%; FY2024: ROIC=-92.0%; FY2025: ROIC=-122.1%✗AkreLatest 3 consecutive FYs: ROIC > 15% in eachReinvestment Rate x ROICN/A (non-positive net income)✗AkreReinvestment Rate * ROIC > 10%ROIC (5-year)0/5 years above 12% (latest -122.1%)✗SleepROIC > 12% in a majority of years - Debt & Leverage42% pass✓ 7✗ 8▾
7 of 12 flag MGTX's debt & leverage — Graham, Buffett, Lynch +4 more
LT Debt vs Net Current Assets✗GrahamLT Debt <= Net Current AssetsDebt/Equity & Interest CoverageD/E: N/A (negative equity), IC: -8.7x✗BuffettD/E < 0.5 AND Interest Coverage > 5xTotal Debt / Equity0.57✗Lynch< 0.33Cash - Long-term Debt✗LynchPositive preferredLT Debt / Total Assets Change0.00% -> 0.00%✓PiotroskiDecreased YoYCurrent Assets / Current Liabilities4.62✓Dreman> 1.5✓SchlossCurrent ratio >= 1.50x (app cutoff)Total Debt / Shareholders' Equity0.57✓Dreman< 0.8✓Templeton< 1.0 (fixed cap; proxy for below-sector-median leverage)✓SchlossD/E < 1.00xDebt Levels0.57✗MungerDebt/Equity < 0.5✗AkreDebt/Equity < 0.3Interest Coverage & Debt/EBITDAIC=-8.7x, D/EBITDA=N/A✗MarksInterest Coverage > 3x; Debt/EBITDA < 4xTotal Debt / Shareholders Equity0.57✓Ackman<= 1.0Negative debt-to-equity (higher means less debt)-0.5666; #2598/4210 (top 61.7%)✗AsnessTop 30% of eligible cross-section
Business & financials
Financial snapshot: annual FY 2025. Current investor scores may use newer quarterly data.
Company Profile
Financial Snapshot
Shareholder Return
Fiscal 2025
Issued 3.3% of shares last year, 26.8% issued over two.
- Buybacks
- —
- Dividends
- —
Company Financials
Latest TTM and quarters alongside annual years
TTM sums four consecutive quarters and uses the latest quarter-end balances. Quarter columns show three-month results; annual columns show full-year totals. Growth compares the same period a year earlier. EPS is not added for TTM; full-year ratios are blank for quarters.
The latest annual period end is unavailable. Showing the latest fiscal cycle’s quarters; quarter and annual columns may overlap. Quarterly shows the full quarter history.
| Metric | TTM · 2026-09-30 2025-10-01 – 2026-09-30 Sources · derived quarter valuesDerived from cumulative filings: revenue, net income, operating income, ebit, interest expense, operating cash flow, depreciation amortization, capex, buybacks. | Q3 FY 2026 2026-07-01 – 2026-09-30 Sources · derived quarter valuesDerived from cumulative filings: operating cash flow, depreciation amortization, capex, buybacks. | Q2 FY 2026 2026-04-01 – 2026-06-30 Sources · derived quarter valuesDerived from cumulative filings: operating cash flow, depreciation amortization, capex, buybacks. | Q1 FY 2026 2026-01-01 – 2026-03-31 Sources | FY 2025Sources
| FY 2024Sources
| FY 2023Sources
| FY 2022Sources
| FY 2021Sources
|
|---|---|---|---|---|---|---|---|---|---|
| Market Cap | $897.2Mcurrent | -- | -- | -- | $619.8Mest. | $496.0Mest. | $389.8Mest. | $406.8Mest. | $669.7Mest. |
| Revenue | $401.9M | $4.8M↑1074% | $321.4M↑8609% | $293.0K | $81.4M↑145% | $33.3M↑137% | $14.0M↓12% | $15.9M↓58% | $37.7M |
| Operating Income | $180.2M↑210% | -$49.9M↓8% | $244.4M↑646% | -$40.8M↑2% | -$106.0M↑35% | -$164.2M↓20% | -$137.1M↓18% | -$116.4M↓60% | -$72.8M |
| Net Income | $78.3M↑146% | -$51.2M↓1% | $160.7M↑514% | -$46.3M↓16% | -$114.2M↑23% | -$147.8M↓76% | -$84.0M↑35% | -$129.6M↓63% | -$79.6M |
| EPS (Diluted) | -- | $-0.53↑15% | $1.71↑456% | $-0.57↓12% | $-1.42↑33% | $-2.12↓42% | $-1.49↑48% | $-2.87↓59% | $-1.80 |
| Gross Margin | — | — | — | — | — | — | — | — | — |
| Operating Margin | 44.8% | -1036.1%↑91% | 76.0%↑106% | -13930.7% | -130.2%↑74% | -493.4%↑50% | -977.8%↓34% | -730.9%↓279% | -193.0% |
| ROE | 36.4%↓91% | — | — | — | 1971.4%↑1005% | -217.9%↓258% | -60.8%↑45% | -110.1%↓157% | -42.9% |
| Total Debt | $121.9M↑65% | $121.9M↑65% | $100.0M↑36% | $74.6M↑1% | $74.3M↑2% | $73.2M↑2% | $72.1M↑2% | $71.0M↑591842% | $12.0K |
| Shareholders' Equity | $215.2M↑631% | $215.2M↑631% | $215.8M↑7190% | -$58.1M↓276% | -$5.8M↓109% | $67.8M↓51% | $138.2M↑17% | $117.7M↓36% | $185.4M |
| Current Ratio | 4.62↑1969% | 4.62↑1969% | 3.76↑327% | 0.55↓64% | 0.75↓63% | 2.03↓15% | 2.38↑27% | 1.88↓30% | 2.69 |
| Debt / Equity | 0.57↑131% | 0.57↑131% | 0.46↓98% | -1.28↓158% | -12.83↓1289% | 1.08↑107% | 0.52↓13% | 0.60↑932025% | 0.00 |
| Operating Cash Flow | $1.4M↑101% | -$24.5M↓101% | -$38.5M↑12% | $17.8M↑148% | -$46.4M↑56% | -$104.5M↑1% | -$105.4M↓44% | -$73.1M↓594% | -$10.5M |
| Free Cash Flow | -$3.0M↑98% | -$26.3M↓105% | -$38.9M↑14% | $15.8M↑141% | -$50.2M↑54% | -$109.5M↑13% | -$125.5M↓6% | -$118.1M↓108% | -$56.9M |
Score history
Historical Score Timeline
Industry peers
Industry Peers
Similar companies in Pharmaceutical Products
MGTX vs Peers — Financial Grading
| Company | Market Cap | Price | Revenue | Net Income | ROE | D/E | Op. Margin | Curr. Ratio | Graham | Buffett | Lynch | Greenblatt | Piotroski | Dreman |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Merck & Co., Inc.MRK | $364.3B | $147.76 | $65.0B | $18.3B | 34.7% | 0.94 | — | 1.54 | 2/9 | 5/9 | 4/7 | 0/3 | F-Score 4 | 1/11 |
| ABBOTT LABORATORIESABT | $188.0B | $108.52 | $44.3B | $6.5B | 12.5% | 0.25 | 18.2% | 1.58 | 3/9 | 4/9 | 2/7 | 1/3 | F-Score 5 | 3/11 |
| BRISTOL MYERS SQUIBB COBMY | $129.7B | $63.43 | $48.2B | $7.1B | 38.2% | 2.44 | 19.4% | 1.26 | 2/9 | 1/9 | 3/7 | 1/3 | F-Score 8 | 5/11 |
| BIO-TECHNE CorpTECH | $11.4B | $72.80 | $1.2B | $73.4M | 3.8% | — | 8.4% | 3.46 | 4/9 | 3/9 | 3/7 | 0/3 | F-Score 5 | 4/11 |
| REPLIGEN CORPRGEN | $10.7B | $167.79 | $738.3M | $48.9M | 2.3% | 0.26 | 7.5% | 8.37 | 3/9 | 2/9 | 3/7 | 0/3 | F-Score 7 | 5/11 |
| IONIS PHARMACEUTICALS INCIONS | $4.8B | $29.06 | $943.7M | $381.4M | -78.0% | 3.60 | -40.4% | 3.83 | 3/9 | 1/9 | 1/7 | 0/3 | F-Score 4 | 3/11 |
| NEOGEN CORPNEOG | $2.5B | $11.23 | $870.4M | $7.9M | -0.4% | 0.76 | -2.5% | 3.82 | 3/9 | 1/9 | 2/7 | 0/3 | F-Score 6 | 4/11 |
| Pharvaris N.V.PHVS | $2.4B | $33.36 | — | $206.4M | -64.8% | 0.00 | — | — | 0/9 | 0/9 | 2/7 | 0/3 | F-Score 2 | 2/11 |